The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children’s Oncology Group Study AALL0232.
E. C. Larsen
No relevant relationships to disclose
W. L. Salzer
No relevant relationships to disclose
M. Devidas
No relevant relationships to disclose
J. B. Nachman
Honoraria - Sigma-Tau
E. A. Raetz
No relevant relationships to disclose
M. L. Loh
No relevant relationships to disclose
N. A. Heerema
No relevant relationships to disclose
A. J. Carroll
No relevant relationships to disclose
J. M. Gastier-Foster
Research Funding - Children's Oncology Group
M. J. Borowitz
Research Funding - BD Biosciences
B. L. Wood
Research Funding - BD Biosciences
C. L. Willman
No relevant relationships to disclose
N. J. Winick
No relevant relationships to disclose
S. Hunger
No relevant relationships to disclose
W. L. Carroll
No relevant relationships to disclose